News Alexion price cut opens up Strensiq to more patients Managed access scheme will control costs to NHS.
News Akari soars ahead of read-out for Soliris rival Investors are anticipating good news from a potential rival to Alexion’s rare disease blockbuster Soliris, with shares in the company behind it soaring.
News Alexion appoints former Baxalta chief Hantson as CEO Former AZ chief David Brennan expected to take over as chairman in May.
News Pharma must slash rare disease drug prices - patient organis... More rare disease drugs must also be approved, says EURORDIS.
News NICE rejects second Alexion ultra-rare disease drug NHS will not fund Kanuma for rare disease LAL-D.
News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
